Judith Creba holds a PhD in Biochemistry from Birmingham University (UK) and worked for 5 years in Research in the Pharmaceutical Industry in the areas of Neuroscience, Cardiovascular and Metabolism before joining the Regulatory Affairs group at Novartis in Basel.
Judith has more than 25 years experience in drug development, regulatory affairs and strategy. She has worked in a range of therapeutic areas, including Oncology, Infectious Diseases, Cardiovascular and Metabolism where she has been involved in the development and approval of a number of products, as well as post- marketing activities. Judith has been responsible for EU Regulatory Policy for a number of years and has represented Novartis on a number of trade association committees, including the EFPIA European Regulatory Liaison Committee. She is currently vice-chair of the EFPIA Clinical Trials and Transparency Priority Working Group.
She has been active in TOPRA since 2009 as a member of the Working Party for the TOPRA/EMA meeting and an observer on the TOPRA Board in 2013.